Jul 29, 2025 06:35AM H.C. Wainwright Downgrades Adaptimmune Therapeutics plc (ADAP) to Neutral

Jul 28, 2025 07:33AM Adaptimmune to sell cell therapy assets to US WorldMeds for $55 million

Jul 28, 2025 07:30AM Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Jun 25, 2025 04:06PM Mizuho Downgrades Adaptimmune Therapeutics plc (ADAP) to Neutral

May 13, 2025 05:47PM Adaptimmune Therapeutics (ADAP) Tops Q1 EPS by 9c

May 13, 2025 07:30AM Adaptimmune Reports Q1 Financial Results and Provides Business Update

May 7, 2025 12:00PM Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Apr 1, 2025 06:47AM Adaptimmune Therapeutics plc (ADAP) PT Lowered to $3 at H.C. Wainwright

Mar 26, 2025 06:57AM Adaptimmune Therapeutics plc (ADAP) PT Lowered to $1.75 at Guggenheim

Mar 21, 2025 06:57AM Adaptimmune Therapeutics plc (ADAP) PT Lowered to $1.40 at Scotiabank

Mar 20, 2025 11:30AM Mizuho Reiterates Outperform Rating on Adaptimmune Therapeutics plc (ADAP)

Mar 20, 2025 07:00AM Adaptimmune Provides Q4 and Full Year 2024 Business Update

Mar 12, 2025 04:54PM Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Jan 30, 2025 04:00PM Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Jan 13, 2025 08:04AM Adaptimmune Therapeutics (ADAP) Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel

Jan 13, 2025 08:00AM Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Dec 19, 2024 07:30AM Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Dec 2, 2024 04:00PM First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Nov 27, 2024 06:34AM Adaptimmune Therapeutics plc (ADAP) PT Lowered to $1.50 at Mizuho

Nov 14, 2024 06:59AM Adaptimmune Therapeutics plc (ADAP) PT Lowered to $3.50 at H.C. Wainwright

Nov 13, 2024 09:02PM Adaptimmune Therapeutics (ADAP) Reports In-Line Q3 EPS

Nov 13, 2024 04:05PM Adaptimmune Reports Q3 2024 Financial and Business Updates

Nov 13, 2024 09:03AM Adaptimmune Therapeutics (ADAP) Reports Lete-cel Achieved Primary Endpoint in Pivotal Trial

Nov 13, 2024 09:00AM Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Nov 5, 2024 09:19AM Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Oct 31, 2024 05:20PM Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Aug 28, 2024 08:00AM Adaptimmune to Participate in Two Bank Conferences this September

Aug 12, 2024 07:11AM Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 9c

Aug 12, 2024 07:00AM Adaptimmune Reports Q2 2024 Financial and Business Updates

Aug 5, 2024 08:00AM Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Aug 1, 2024 08:27PM Adaptimmune Therapeutics (ADAP) Receives FDA Accelerated Approval of TECELRA

Jul 19, 2024 01:41PM Adaptimmune Therapeutics plc (ADAP) PT Raised to $2.50 at Jones Trading